The experience of the use of denosumab in the treatment of patients with rheumatoid arthritis with osteoporosis
Therapy of rheumatoid arthritis (RA) is directed not only to suppress inflammation, but also to prevent the loss of bone mineral density (BMD). Denosumab, a promising and principally new drug for the treatment of secondary osteoporosis (OP), which reffers to the group of genetically engineered biological preparations and is a monoclonal antibody binding RANKL. As a result, the interaction of RANKL with its receptor is disturbed, which leads to a decrease in the activity of osteoclasts and a decrease in the resorption of bone tissue. The article presents the results of evaluation of the effect of densomab on the BMD of the axial and peripheral skeleton of RA patients with OP. It was shown that therapy with dosumab 60 mg subcutaneously 2 times a year with an interval of 6 months between injections allowed to significantly increase the BMD in the lumbar spine and the femoral neck, and also to stabilize the BMD in the distal forearm of RA patients with OP regardless of glucocorticosteroid intake.